IRF5 POLYMORPHISMS IN SYSTEMIC SCLEROSIS

Carmel Stock(Guy's and St Thomas' NHS Foundation Trust), Carmen Fonseca, Gisela Lindahl(Royal Brompton Hospital), Hajime Satō(National Institute of Public Health), CP Denton(The Royal Free Hospital), Dietmar Abraham(Medical University of Vienna)

UCL Discovery (University College London)

March 1, 2013

Cited by 0

Related Papers

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

|Annals of the Rheumatic Diseases|2003|769

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

|Annals of the Rheumatic Diseases|2010|503

Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation

|Journal of Biological Chemistry|2000|219

Activation of Fibroblast Procollagen α1(I) Transcription by Mechanical Strain Is Transforming Growth Factor-β-dependent and Involves Increased Binding of CCAAT-binding Factor (CBF/NF-Y) at the Proximal Promoter

|Journal of Biological Chemistry|2002|148

Subclinical neurophysiological effects of lead: A review on peripheral, central, and autonomic nervous system effects in lead workers

|American Journal of Industrial Medicine|2000|142